靶向GD2的CAR T细胞治疗高危神经母细胞瘤:一项1/2期试验
该1/2期试验纳入35例高危转移性、复发或难治性神经母细胞瘤患儿,并在医院豁免条件下按相同标准治疗19例额外患儿。结果显示GD2-CART01可诱导持久缓解,最大耐受剂量为每公斤10×10^6个CAR阳性细胞,试验队列客观缓解率为66%,中位随访4.2年时5年总生存率为42.67%。
要点
- 最大耐受剂量为每公斤10×10^6个CAR阳性细胞,未观察到新的安全性信号。
- 试验队列客观缓解率为66%(21/32,排除3例无疾病证据者),6周、3个月和6个月完全缓解率分别为37%、34%和40%。
- 目标人群(低疾病负荷、每公斤10×10^6个细胞)客观缓解率为77%,5年总生存率和无事件生存率分别为68%和53%。
核心结论
- GD2-CART01可在高危转移性、复发或难治性神经母细胞瘤患儿中诱导持久缓解。
研究设计与样本
- 1/2期临床试验,最终分析纳入全部35例入组患者,并在医院豁免条件下按相同标准治疗19例额外患儿。
- 主要终点为安全性、最大耐受剂量、不同时间点的客观缓解率和完全缓解率;次要终点包括5年总生存率和GD2-CART01持久性。
主要发现
- 未观察到新的安全性信号;4例患儿诊断为3级免疫效应细胞相关神经毒性综合征,经利米杜西激活诱导型半胱天冬酶-9自杀基因后迅速控制。
- 最大耐受剂量为每公斤10×10^6个CAR阳性细胞。
- 试验入组患者客观缓解率为66%(21/32,排除3例无疾病证据者);6周、3个月和6个月完全缓解率分别达37%、34%和40%。
- 试验入组患者中64%的GD2-CART01持久存在≥12个月。
- 中位随访4.2年,试验队列5年总生存率为42.67%。
关键数值与推荐
- 目标人群定义为低疾病负荷且接受每公斤10×10^6个GD2-CART01细胞治疗者,共54例儿童中38例,包括8例一线治疗后无疾病证据巩固治疗者。
- 目标人群客观缓解率为77%,5年总生存率和无事件生存率分别为68%和53%。
- 接受一或两线治疗者较接受≥3线治疗者的5年总生存率和无事件生存率显著更优。
- 淋巴细胞采集在诊断时进行者的结果更好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antidisialoganglioside (GD2), third-generation chimeric antigen receptor (CAR) T cells (GD2-CART01) have shown encouraging efficacy in children with high-risk metastatic, relapsed, or refractory neuroblastoma in the interim analysis of a phase 1/2 clinical trial. We now present the final results obtained in all 35 patients enrolled and in 19 additional children selected with the same criteria of the trial and treated in a hospital exemption setting. Primary endpoints for the trial were safety, maximum tolerated dose, overall response rate (ORR) and complete remission rate at various timepoints. Secondary endpoints included 5-year overall survival (OS) and persistence of GD2-CART01. No new safety signals were observed. Grade 3 immune effector cell-associated neurotoxicity syndrome was diagnosed in four children and rapidly controlled with the activation of the inducible caspase-9 suicide gene by rimiducid. The maximum tolerated dose was 10 × 106CAR+ cells per kg. The ORR of the patients enrolled in the clinical trial was 66% (21/32-excluding the three patients treated in nonevidence of disease). The complete remission rate at 6 weeks, 3 months and 6 months reached 37%, 34% and 40%, respectively. GD2-CART01 persisted ≥12 months in 64% of the patients enrolled in the clinical trial. With a median follow-up of 4.2 years, the 5-year OS for the trial cohort was 42.67%. In total, 38 of 54 children were treated with low disease burden at 10 × 106 GD2-CART01 cells per kg (defined as the target population), including eight patients consolidated in nonevidence of disease after the first line. The ORR in the target population was 77%, the 5-year OS and event-free survivals were 68% and 53%, respectively. Substantially superior 5-year OS and event-free survivals were observed in patients treated after one or two lines of therapy versus those treated after ≥3 lines of therapy. Better results were observed in patients whose lymphocyte collection was performed at the time of diagnosis. These results confirm that GD2-CART01 can induce durable remissions in children with high-risk metastatic, relapsed, or refractory neuroblastoma. ClinicalTrials.gov identifier: NCT03373097 .
引用
- Locatelli F, Pagliara D, De Ioris MA, et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial. Nat Med. 2025. PMID: 40841488. doi:10.1038/s41591-025-03874-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。